Mizuho analyst Graig Suvannavejh raised the firm’s price target on Terns Pharmaceuticals (TERN) to $33 from $32 and keeps an Outperform rating on the shares following the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals Reports Q3 2025 Results and Updates
- Terns Pharmaceuticals price target raised to $28 from $27 at Barclays
- Promising Outlook for Terns Pharmaceuticals: Buy Rating Backed by Strong Financials and Potential Breakthrough in Leukemia Treatment
- Terns Pharmaceuticals reports Q3 EPS (27c), consensus (30c)
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV